Abstract
Cardiovascular and renal diseases share common pathophysiological grounds, risk factors, and therapies. The 2 entities are closely interlinked and often coexist. The prevalence of kidney disease among cardiac patients is increasing. Patients have an atypical clinical presentation and variable disease manifestation versus the general population. Renal impairment limits therapeutic options and worsens prognosis. Meticulous treatment and close monitoring are required to ensure safety and avoid deterioration of kidney and heart functions. This review highlights recent advances in the diagnosis and treatment of cardiac pathologies, including coronary artery disease, arrhythmia, and heart failure, in patients with decreased renal function.
Keywords:
CKD; Cardiovascular disease; Chronic kidney disease; Chronic renal failure; Coronary artery disease; Heart failure; Renal disease.
Copyright © 2020 Elsevier Inc. All rights reserved.
MeSH terms
-
Aged
-
Aminobutyrates / therapeutic use
-
Angiotensin Receptor Antagonists / therapeutic use
-
Biphenyl Compounds
-
Cardiovascular Diseases / complications*
-
Cardiovascular Diseases / epidemiology
-
Cardiovascular Diseases / physiopathology
-
Cardiovascular Diseases / therapy
-
Contrast Media / adverse effects*
-
Drug Combinations
-
Factor Xa Inhibitors / pharmacokinetics
-
Female
-
Humans
-
Male
-
Percutaneous Coronary Intervention / adverse effects*
-
Prevalence
-
Prognosis
-
Renal Insufficiency, Chronic / complications*
-
Renal Insufficiency, Chronic / epidemiology
-
Renal Insufficiency, Chronic / physiopathology
-
Renal Insufficiency, Chronic / therapy
-
Risk Factors
-
Sodium-Glucose Transporter 2 Inhibitors / therapeutic use
-
Tetrazoles / therapeutic use
-
Valsartan
Substances
-
Aminobutyrates
-
Angiotensin Receptor Antagonists
-
Biphenyl Compounds
-
Contrast Media
-
Drug Combinations
-
Factor Xa Inhibitors
-
Sodium-Glucose Transporter 2 Inhibitors
-
Tetrazoles
-
Valsartan
-
sacubitril and valsartan sodium hydrate drug combination